Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2023-05-23 | Asarina Pharma | Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-22 | Asarina Pharma | Kommuniké från årsstämma i Asarina Pharma AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-22 | Asarina Pharma | Bulletin from the Annual General Meeting of Asarina Pharma AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-05 | Asarina Pharma | Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-28 | Asarina Pharma | Asarina Pharma AB (publ) releases Annual Report 2022 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-28 | Asarina Pharma | Asarina Pharma AB (publ) årsredovisning 2022 publicerad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-18 | Asarina Pharma | Asarina Pharma: KALLELSE TILL ÅRSSTÄMMA I ASARINA PHARMA AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-18 | Asarina Pharma | Asarina Pharma: NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-01 | Asarina Pharma | Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-01 | Asarina Pharma | Asarina Pharma publicerar positiva resultat från sin fas IIa-studie av Sepranolon i Tourette syndrom | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-27 | Asarina Pharma | Asarina Pharma AB (publ) släpper bokslutskommuniké för 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-02-27 | Asarina Pharma | Asarina Pharma AB (publ) releases Year-End Report 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-02-02 | Asarina Pharma | Asarina Pharma: Sista patientens sista besök i Tourette syndrom-studien | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-02 | Asarina Pharma | Asarina Pharma: Last Patient Last Visit for landmark Tourette Syndrome study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-14 | Asarina Pharma | Asarina Pharma: Full rekrytering och sista patienten randomiserad i den viktiga studien om Tourettes syndrom | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-14 | Asarina Pharma | Asarina Pharma: Patient recruitment completed in landmark Tourette syndrome study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-06 | Asarina Pharma | Extensive new preclinical study significantly increases the Translatability of Asarina Pharma's findings on key stress mechanism implicated in Tourette Syndrome and OCD | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-06 | Asarina Pharma | Omfattande ny preklinisk studie ökar säkerheten av Asarina Pharmas resultat om en viktig stressmekanism involverad i Tourettes syndrom och OCD | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-25 | Asarina Pharma | Asarina Pharma AB (publ) Rapport för andra kvartalet 2022 släppt | Rapporter | Ladda ner | Visa Stäng |
|
||||
2022-08-25 | Asarina Pharma | Asarina Pharma AB (publ) Q2 2022 Report released | Rapporter | Ladda ner | Visa Stäng |
Rapporter |
Asarina Pharma AB (publ) Q2 2022 Report releasedFINANCIAL HIGHLIGHTS
R&D HIGHLIGHTS TOURETTE SYNDROME
CEO Peter Nordkild: ”If full clinical development is successful, Sepranolone will be the first endogenous, neuroendocrinological compound used to treat Tourette. As such it would represent an entirely new treatment modality – with no serious side effects. We would like to thank the ongoing commitment of our volunteer patients and our excellent teams at Bispebjerg and Herlev University hospitals in Copenhagen.” To read the Report in full please visit: https://asarinapharma.com/investors/financial-reports/ |